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Abstract
Objective This study aimed to (1) compare the agreement of
two evaluation methods of metabolic response in patients with
non-small cell lung cancer (NSCLC) and determine their
prognostic value and (2) explore an optimal cutoff of meta-
bolic reduction to distinguish a more favorable subset of
responders.
Methods This is a secondary analysis of prospective studies.
Enrolled patients underwent 18F-PET/CTwithin 2 weeks be-
fore, during, and months after radiotherapy (post-RT). Meta-
bolic response was assessed using both Peter MacCallum
(PM) method of qualitative visual assessment and University
of Michigan (UM) method of semiquantitative measurement.
The agreement between two methods determined response,
and their prediction of outcome was analyzed.
Results Forty-four patients with median follow-up of
25.2 months were analyzed. A moderate agreement was
observed between PM- and UM-based response assessment
(Kappa coefficient=0.434), unveiling a significant difference
in CMR rate (p=0.001). Categorical responses derived from
either method were significantly predictive of overall survival
(OS) and progression-free survival (PFS) (p<0.0001). Nu-
merical percentage decrease of FDG uptake also showed sig-
nificant correlations with survival, presenting a hazard ratio of
0.97 for both OS and PFS. A 75 % of SUV decrease was
found to be the optimal cutoff to predict OS and 2-year
progression.
Conclusions There was a modest discrepancy in metabolic
response rates between PM and UM criteria, though both
could offer predictive classification for survival. The percent-
age decrease provides an ordinal value that correlates with
prolonged survival, recommending 75 % as the optimal
threshold at identifying better responders.
Keywords PET/CT . Non-small cell lung cancer . Metabolic
response . Overall survival . Progression-free survival
Introduction
18F-fluorodeoxyglucose positron emission tomography/
computed tomography (FDG PET/CT)-based metabolic re-
sponse has been reported to be a prognostic indicator for pa-
tients with non-small cell lung cancer (NSCLC) by a large
number of studies [1–22]. However, there is a wide variation
in the measurement of tumor FDG uptake and the stratifica-
tion into response categories, resulting in the fact that multiple
criteria for metabolic response evaluation are proposed and
applied diversely among clinical centers. Currently, methods
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for evaluating metabolic response on FDG-PET include qual-
itative visual assessment such as Peter MacCallum (PM)
criteria [5], semiquantitative assessment using reduction of
metabolic activity (e.g., SUV) such as EORTC [23], Univer-
sity of Michigan (UM) [10], and PERCIST [24] methods, and
quantitative evaluation using kinetic modeling [25].
Quantitative method of kinetic modeling or Patlak plot is
used infrequently in clinical practice due to the complexity,
including the needs for arterial blood sampling or dynamic
imaging of a blood-pool structure to acquire a precise input
function [25]. The best method of metabolic response evalu-
ation is currently unknown, both for predicting outcome and
being easily applicable into routine clinic practice. All of the
aforementioned response criteria are currently being used in
clinical practice, and there was no direct cross-comparison
between the various methods yet.
With regard to semiquantitative assessment, many studies
have reported that over 70 % of NSCLC patients underwent at
least 30 % of posttreatment decrease in metabolic activity,
namely the partial metabolic response (PMR) by semiquanti-
tative evaluation methods [9, 10, 13, 17, 20]. This indicates
that the current cutoff values of 25 or 30 % of metabolic
decrease for PMR are probably too modest or insufficient to
identify medically relevant response. Given this consider-
ation, it would be advantageous to explore another reliable
cutoff value that might allow distinguishing a subgroup of
PMR patients with more favorable outcome.
This study aimed to (1) compare response rates of PM (a
qualitative method) and UM method (a semiquantitative) on
FDG PET/CT and examine their value for predicting long-
term outcome and (2) perform a post hoc analysis to explore
an optimal cutoff for the selection of better responders in
NSCLC treated with definitive radiotherapy.
Methods
Study population
The patients in this study represented a cohort from a series of
functional imaging-related prospective studies between 2003
and 2010 at the University of Michigan (UM). These studies
were approved by the institutional review board (IRB) of the
University of Michigan, and written informed consent was
obtained from each patient. Unresectable or inoperable stage
I–III NSCLC patients receiving definitive radiation therapy
(RT) underwent FDG PET/CT scans within 2 weeks prior to
RT beginning (pre-RT PET/CT) and at the fourth week during
RT as per protocol. After treatment, patients were followed up
with CT with or without PET/CT per physician’s discretion,
and those with PET/CT scans within 6 months after RT (post-
RT PET/CT) were eligible for the present analysis. Exclusion
criteria included prior thoracic RT history, small cell
carcinoma histology, and comorbidity of diabetes mellitus
with uncontrolled blood glucose level >200 mg/dL. All pa-
tients had a definitive course of radiotherapy under standard
practice or per protocol. As we are focusing on posttreatment
response assessment, we did not restrict the RT regimens.
PET/CT image acquisition
FDG PET/CT scans were performed at two institutions:
University of Michigan Hospital (UMH) and Veterans Ad-
ministration Health Center/Veterans Affairs Medical Cen-
ter, Ann Arbor (VA-AA) between 2003 and 2010. The PET
protocols used at both institutions were standardized
throughout this time period. Details of the PET/CT scan
protocols have been previously described [10]. At the
UMH between 2003 and 2006, the PET/CT imaging was
performed on a Siemens Biograph Classic (Siemens Medi-
cal Solutions, Hoffman Estates, IL, USA) and between
2006 and 2010 on a Siemens Biograph T6. All PET/CT
studies at the VA Ann Arbor Medical Center were per-
formed on a Siemens Biograph T6.
Image interpretation and response evaluation
Interpretation of PET/CT imagings was performed by nuclear
medicine physicians blinded to clinical information using con-
sensus criteria. Mean SUV (SUVmean) within a circular region
of interest (ROI) of about 1.0-cm diameter placed in the aorta
arch (AA) was used to represent the metabolic activity of
mediastinal blood pool (MBP) for purpose of normalization.
Tumor FDG uptake expressed as normalized maximum SUV
(SUVmax) to AA (NSUV-A) was calculated using the follow-
ing formula [10, 26, 27]:
NSUV−A ¼ SUVmax of ROI tumorð Þ=SUVmean AAð Þ
Each patient’s set of PET/CT studies was evaluated twice
using PM and UM methods, respectively [5, 10]. The numer-
ical percentage decline of NSUV-A was also analyzed as a
continuum.
Statistical analysis
Kappa coefficient was used to estimate the agreement between
PM and UM evaluation systems. Overall response to treat-
ment (ORTT) was determined based on primary tumor (T),
regional lymph nodes (N), and distant status (M). Infield re-
sponse to treatment (IFRTT) was defined as the response to
treatment regarding only lesions within the radiation field. For
instance, the case in which new lesions appear and progress
despite apparent remission of the local disease would be clas-
sified as PMDofORTTwhereas CMR of IFRTT.We explored
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2-year progression as the endpoint to separate study patients
into two groups (early progression vs. late progression). Re-
ceiver operating characteristic (ROC) analysis was used to
identify the optimal cutoff in percentage decline of NSUV-A
to discriminate the two groups. Kaplan–Meier survival analy-
sis and log-rank test were performed to compare survival be-
tween different groups. Using cutoffs varying from 25 to 90%
reduction of NSUV-A at 5 % increments, the discriminative
values of various cutoffs were analyzed for both overall sur-
vival (OS) and progression-free survival (PFS) by Kaplan–
Meier method. Cox proportional hazard regression was ren-
dered to investigate the prognostic significance of various re-
sponse systems. A p≤0.05 was considered statistically signif-
icant, and all tests were two-tailed.
Results
General characteristics
A total of 118 patients were enrolled in the prospective stud-
ies, and eventually, 44 patients with both pre- and post-RT
scans were eligible for this analysis. Table 1 shows the demo-
graphics and tumor characteristics for the study population.
There were 6 patients with adenocarcinoma, 10 with
squamous cell carcinoma, 1 with large cell carcinoma, and
23 with NSCLC but unknown subtype, primarily due to the
limited specimen obtained from fine needle aspiration-based
biopsy. In addition, four patients had clinically diagnosed
NSCLC based on the consensus of tumor board but without
pathological verification because of unfitness for biopsy. The
median RT dose was 70 Gy. The interval between RTend and
post-RT PET/CT scan ranged from 45 to 176 days, with a
median of 93 days.
Comparison of categorical metabolic response assessment
by PM and UM methods
According to PM methods using qualitative visual assess-
ment, the rates of CMR, PMR, SMD, and PMD were 38.6,
52.3, 2.3, and 6.8 %, respectively. For UMmethod, they were
13.6, 72.7, 9.1, and 4.5 %, respectively. A significant differ-
ence in CMR rate was observed between the UM and PM
methods (p=0.001), while no significant differences were
seen for PMR, SMD, and PMD. The distribution of ORTT
between PM and UM criteria is shown in Table 2, with an
agreement rate of 68.1 % (30/44) and a Kappa coefficient of
0.434. Figure 1 graphs the actual change in NSUV-Awith the
corresponding response categories of ORTTand IFRTT deter-
mined by PM criteria, with the discrepancy in-between that
resulted from two cases with infield CMR (58.4 and 87.1 %
reduction in NSUV-A, respectively) but with out-of-field
failure.
Categorical response and survival
The median follow-up time for the study population was
25.2 months. Figure 2a, b depicts that both PM and UM
methods determined response classification were predictive
of OS (p<0.0001). Patients with CMR achieved significantly
better outcome than the non-CMR population. The median
survival (MS) was 48.1 and 18.3 months for PM criteria-
based CMR and non-CMR patients (p=0.016). By the end
of the last follow-up, the MS was not reached for UM
criteria-determined CMR patients and was 22.0 months for
non-CMR patients (p=0.086). Similar findings were observed
with respect to PFS results. Both PM and UM method-based
response classifications were predictive of PFS (p<0.0001)
(Fig. 2c, d). The CMR group compared to the non-CMR
group had median PFS of 33.7 months vs. 8.4 months
(p=0.005) for PM criteria and 25.5 vs. 12.4 months,
respectively (p=0.231), for UM criteria.
Combining PM and UM criteria, we divided the patients
into three groups: (1) those achieving CMR under both criteria
(visual CMR and NSUV-A≤1), (2) those identified as CMR
using PM system but non-CMR using UM criteria (visual
CMR but NSUV-A>1), and (3) the remaining patients as
CMR in neither group (neither visual CMR nor NSUV-A≤1)
Table 1 General characteristics
Characteristics Number of
patients (%)
Age 70 (47, 87)a
Gender Male 36 (81.8 %)
Female 8 (18.2 %)
Histology Adenocarcinoma 6 (13.6 %)
SCC 10 (22.7 %)
NSCLC-NOS 23 (52.3 %)
Large cell carcinoma 1 (2.3 %)
Unknown 4 (9.1 %)
Stage I 10 (22.7 %)
II 9 (20.5 %)
III 25 (56.8 %)
RT dose 70.0 (50b, 85.5)
Concurrent chemotherapy Yes 24 (54.5 %)
No 20 (45.5 %)
Post-RT scan interval (days) 93 (45, 176)
SCC squamous cell cancer, NSCLC-NOS non-small cell lung cancer-not
otherwise specified
a Presented as median (range)
b Four patients underwent the stereotactic body radiation therapy (SBRT)
including two with 11 Gy×5, one treatedwith 10Gy×5, and another with
20 Gy×3
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for further survival analysis. A significant difference among
the three groups was observed, with regard to both OS (p=
0.044, Fig. 2e) and PFS (p=0.019, Fig. 2f), which was mainly
resulted from the inferior outcome of non-CMR classification
(neither visual CMR nor NSUV-A≤1).
Optimal cutoff for prediction of progression and survival
Cox regression analysis showed a positive correlation be-
tween the numerical percentage decrease of NSUV-A and
survival, resulting in the hazard ratio (HR) of 0.971 (95%CI,
0.955–0.988) and 0.971 (95%CI, 0.957, 0.986) from 1 % re-
duction of NSUV-A for OS and PFS, respectively. ROC anal-
ysis identified 75 % decrease in NSUV-A as the optimal cut-
off, translating into a sensitivity of 80 % and specificity of
69 % for the 2-year progression (Fig. 3a). The discriminative
values of cutoffs varying from 25 to 90% reduction of NSUV-
A at 5 % increments were analyzed for both OS and PFS.
Besides the 25 % decrease proposed by EORTC criteria, a
threshold of 75 and 60 % reduction was found by OS
(p=0.002) and PFS (p<0.0001) analyses, respectively, to in-
troduce the most discriminative significance (Fig. 3b, c).
Using 25 and 75 % reduction as the cutoffs to stratify patients
into three subgroups, we saw significantly different OS
(Fig. 4a, 70.7 vs. 20.5 vs. 7.6 months, p<0.0001) and PFS
(Fig. 4b, 25.5 vs. 8.4 vs. 4.6, p<0.0001) across groups.
Discussion
This study demonstrated a remarkable discrepancy in CMR
rates between PM (qualitative visual assessment) and UM
methods (semiquantitative assessment). Both criteria can dis-
tinguish patients with different outcomes providing important
prognostic information, although the predictability may be
considered somewhat coarse and suboptimal. As a continuum,
the actual percentage change of metabolic activity was also
shown to be predictive of survival, and a 75 % decline was
found to be the optimal threshold to predict 2-year progression
and the overall survival in this NSCLC patient cohort treated
with definitive RT.
Metabolic response has been broadly applied in clinical
studies and increasingly used in clinical practice as well. How-
ever, there is little literature investigating the agreement across
various response evaluation methods and comparing their pre-
dictive value for outcome. To our knowledge, there were two
published studies currently making the direct comparison of
the concordance and the prognostic significance between
Table 2 Agreement between Peter MacCallum and UM evaluation systems
Peter MacCallum
UM CMR PMR SMD PMD Total
No. % No. % No. % No. % No. %
CMR 6 100 % 0 0 % 0 0 % 0 0 % 6 13.6 %
PMR 11 34.4 % 21 63.6 % 0 0 % 0 0 % 32 72.7 %
SMD 0 0 % 2 50.0 % 1 25.0 % 1 25.0 % 4 9.1 %
PMD 0 0 % 0 0 % 0 0 % 2 100 % 2 4.5 %
Total 17 38.6 % 23 52.3 % 1 2.3 % 3 6.8 % 44 100 %
CMR complete metabolic response, PMR partial metabolic response, SMD stable metabolic disease, PMD progressive metabolic disease
Fig. 1 Actual percentage change
in NSUV-A versus corresponding
individual response categories
determined by PM criteria. a
Overall response to treatment
(ORTT) grouping. b Infield
response to treatment (IFRTT)
grouping
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EORTC and PERCIST criteria [28, 29]. Skougaard and col-
leagues found that response evaluation with EORTC criteria
and PERCIST gave similar responses and OS outcomes with
good agreement on best overall metabolic response in meta-
static colorectal cancer treated with irinotecan and cetuximab
[28]. Another study enrolling 29 patients with small cell lung
cancer demonstrated a perfect concordance between EORTC
and PERCIST criteria (kappa coefficient=1) [29].
Different from the abovementioned studies, our study
made a comparison between the qualitative and semiquantita-
tive methods. Our results revealed a moderate agreement be-
tween two methods whereas significantly higher CMR rate
under PM method-based visual assessment. This finding indi-
cated that the application of various response criteria could
cause different conclusion about the efficacy of the treatment,
which would lead to confusion in interpretation of trial results
or clinical reports and may affect the clinical decision making
for the further treatment such as the maintenance therapy. One
should be cautious when comparing the metabolic response
results across trials without identical evaluation methods.
Our results of 44 patients confirmed findings from previous
studies that metabolic response (either UM or PMmethods) is
predictive of outcome in NSCLC [1–24]. Posttreatment CMR
clearly is associated with the longest survival irrespective of
utilized methods. However, the survival differences in terms
of both OS and PFS between UM criteria defined that CMR
and non-CMR groups in our study did not reach statistical
significance. Further stratification dividing PM criteria deter-
mined CMR patients into two subgroups (visual CMR and
NSUV-A≤1 vs. visual CMR but NSUV-A>1) that failed to
find further distinction in the context of OS or PFS, suggesting
that the semiquantitative assessment of CMRmay be too strict
to miss good responders with only mild FDG uptake
undiscerned by visual evaluation.
Interestingly, our findings demonstrated that the actual per-
centage reduction in NSUV-A was positively correlated with
Fig. 2 Overall survival of PM (a)
and UM (b) criteria-based
response categories. Progression-
free survival of PM (c) and UM
(d) criteria-based response
categories. Overall survival (e)
and progression-free survival (f)
of subgroups defined by
combining PM and UM criteria
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OS and PFS in a continuous variable model, which was con-
sistent with the findings of ACRIN 6668/RTOG 0235 Trial
[30]. This suggests that every single percent of metabolic ac-
tivity reduction may confer a certain survival advantage and
the relationship between tumor metabolic change and progno-
sis may be continuous rather than having a fixed cutoff point.
Nonetheless, the categorical classification of metabolic re-
sponse is a practical approach for evaluating treatment effica-
cy and guiding clinical decisions in daily care.
In this study, we validated that less than 25 or 30 % de-
crease in metabolic activity applied by EORTC and UM
criteria would have allowed for the discrimination of non-
responders (SMD) from PMR patients. However, many stud-
ies have reported that over 70 % of NSCLC patients
underwent at least 30 % of metabolic decrease [9, 10, 13,
17, 20]. Therefore, it is rational to raise the hypothesis that
there may be a subset of patients with more favorable outcome
in the UM or EORTC criteria determined PMR population.
Several studies have attempted to modify cutoffs of posttreat-
ment metabolic change to optimize the categorical response
evaluat ion. Shira ishi and col leagues found that
postneoadjuvant chemoradiotherapy of 40 % decrease in
SUV could predict pathological response but could not suc-
cessfully predict long-term overall survival [20]. Eschmann
and colleagues proposed postneoadjuvant chemoradiotherapy
where a 65 % decrease in SUV was the optimal cutoff to
distinguish stage III NSCLC patients with distinct outcome
[9]. For stage IV NSCLC, Yoon and colleagues reported that
50% reduction of SUV could predict time to progression [23].
It is valid to speculate that the optimal cutoff value for
Fig. 3 a Optimal cutoff of 75 %
decrease in metabolic activity
identified by receiver operating
characteristic (ROC) analysis for
predicting 2-year progression.
Discriminative values of various
cutoff of percentage decrease for
overall survival (b) and
progression-free survival (c)
Fig. 4 Overall survival (OS) and
progression-free survival (PFS) of
response categories derived from
newly proposed cutoff of 25 and
75 % of NSUV-A reduction
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favorable subset identification in NSCLC patients receiving
definitive chemoradiotherapy should be higher than that in
patients with the non-curative or palliative therapy. Accord-
ingly, our study showed that a 75 % of NSUV decrease pre-
sented the most discriminative significance in terms of OS and
2-year progression prediction. Although a 60% reduction was
found to be the most robust cutoff for PFS prediction, a 75 %
decrease in NSUV still presents adequate value for the iden-
tification of better responder.
We acknowledge several limitations in our study. This
is a secondary analysis of a series of prospective studies.
PET/CT was not required for the follow-up, and thus, no
prospectively defined strict timing was used for the post-
treatment PET/CT study. In the present study, we did not
have the SUV data corrected by lean body mass (SUL)
or body surface area (SUVmax-BSA), and therefore, we
could not evaluate the response using PERCIST or
EORTC methods. However, given the semiquantitative
nature and similar cutoff definition, we would expect a
strong concordance in response classification between
these methods. Further prospective studies are warranted in
a larger and independent cohort to validate our findings and
hypothesis.
Conclusions
There is a moderate agreement between the visual assessment
of PM and semiquantitative inspection of UM criteria for the
metabolic response evaluation, with the main discrepancy of
the CMR rate. Categorical metabolic response is validated to
be strongly predictive of outcome, and visual assessment
seems to be sufficient for CMR identification. The numerical
percentage reduction of metabolic activity provides an ordinal
value that correlates with prolonged survival. At least 75 %
decrease of metabolic activity is indicative for a favorable
long-term outcome, pending validation by an independent
population.
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